Andrew Brooks Chief Operating Officer of RUCDR Infinite Biologics and Director of the Bionomics Research and Technology Center at Rutgers University Session C: Personalized Medicine
Andrew Brooks is the Chief Operating Officer of RUCDR Infinite Biologics and Director of the Bionomics Research and Technology Center at Rutgers University. He is also one of the founding members of the Bioprocessing Solutions Alliance. Dr. Brooks is a molecular neuroscientist whose research focuses on deciphering the molecular mechanisms that underlie memory and learning. Dr. Brooks is a well-recognized genomicist and has been involved in the development and implementation of cutting edge molecular based technologies for nucleic acid and protein analyses.
Susan A. Cole President, Montclair State University Opening Remarks
Dr. Susan A. Cole assumed office in September of 1998 as the eighth president of Montclair State University, which is the second largest university in New Jersey, with over 20,000 graduate and undergraduate students. Dr. Cole served as President of Metropolitan State University in Minneapolis/St. Paul, Minnesota from 1993 to 1998 and, prior to that, as Vice President for University Administration and Personnel at Rutgers, The State University of New Jersey, Associate University Dean for Academic Affairs at Antioch University, and a faculty member at The City University of New York.
Dr. Cole serves on the boards of the Liberty Science Center, the Montclair Art Museum, the New Jersey Performing Arts Center Council of Trustees and Peapack-Gladstone Bank, and on the American Association of State Colleges and Universities Penson Center for Professional Development. She was appointed by Governor Christie as New Jersey’s representative to the Education Commission of the States, and by the U.S. Secretary of the Interior to the Paterson Great Falls National Historical Park Advisory Commission. She served on Governor Christie’s Executive Transition Team and chaired its Education Subcommittee. She also served on the Property Tax Convention Task Force, appointed by Governor McGreevey, as co-chair of Governor McGreevey’s Higher Education Transition Team and on his Education Cabinet, as co-chair of Governor DiFrancesco’s World Class Economy Task Force, and as a member of Governor Whitman’s trade missions to South America and Asia.
Dr. Cole earned three degrees in English and American literature: a B.A. from Barnard College, Columbia University and an M.A. and Ph.D. from Brandeis University. Dr. Cole writes and speaks extensively about current issues in American higher education.
Jason Cooper VP and CAO, Horizon Blue Cross Blue Shield of New Jersey Session D: Healthcare Analytics
Jason Cooper is VP and CAO, Horizon Blue Cross Blue Shield of New Jersey where he is responsible for enterprise-wide data analytics and informatics, including both commercial and government lines of business. He has more than 20 years of experience in analytics and informatics covering for-profit, nonprofit and government domains, including leading teams at Wellmark Blue Cross Blue Shield, Cigna and CVS Health, as well as experience with NASA spaceflight software analyses. Additionally, he is a member of the International Institute for Analytics, the American Medical Informatics Association, Sentrian’s Advisory Board, Cognizant’s Chief Data Officer Advisory Council, an editorial board member for the American Journal of Pharmacy Benefits, and board member of NJ’s American Diabetes Association.
Patrick R. Coyle MBA '05, Global Oncology Controller with Bayer HealthCare Pharmaceuticals Session E: Careers Within Pharma
Patrick R. Coyle, MBA, is the Global Oncology Controller with Bayer HealthCare Pharmaceuticals located in Whippany, NJ. Mr. Coyle is the global financial business partner responsible for product launches, brand support, pipeline development and strategic alliances for Oncology. He began his tenure at Bayer in Global R&D Controlling, where he spent 4 years learning the key drivers of clinical development while overseeing financial performance and portfolio development. He then spent two years as Sr. Finance Manager for US Oncology, incorporating key insights from patients, payers and customers into strategic brand initiatives. He has recently led several projects including an overhaul of the 340B chargeback system to protect against revenue leakage and a re-design of the patient access program for oncology franchise. Prior to joining Bayer, Mr. Coyle held a variety of positions including Finance Director for a public IT company overseeing all aspects of financial operations and external reporting.
John F. Crowley Chairman and Chief Executive Officer, Amicus Therapeutics, Inc. Lunch & Keynote Address
John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.
John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He serves on the Executive Committee of the National Board of Directors of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. He also serves on the Board of Directors of Scioderm, Inc. John is a Henry Crown Fellow at the Aspen Institute.
Rachit Dhir Vice President, Global Consulting/Insurance & Healthcare Session D: Healthcare Analytics
Rachit Dhir is Vice President - Global Consulting and leads Fractal’s consulting practice in Insurance & Healthcare vertical across the US. He has over 14 years of corporate experience in analytics consulting, solution design, business development, and global analytics delivery. Mr. Dhir has led large engagements to deliver high-impact business results for Fortune 500 clients, including Aetna, Anthem, Humana, Allstate, Bloomberg, CVS Caremark, and consulted with CXO and functional head level executives in the development and execution of analytics strategy. He holds an MBA from Indian Institute of Technology, Delhi, and a Bachelor of Engineering, Electronics & Instrumentation Control from Thapar University.
Tina Garyantes, PhD Vice President of Therapeutics at Chromocell Session B: Innovative Applications of Tech in Healthcare
Tina Garyantes, PhD, is Vice President of Therapeutics at Chromocell, a research based therapeutics and flavors company, where she is responsible for most of the company’s research functions and their recently announced multi-million dollar collaboration with Astellas. Prior to joining Chromocell, she was CEO of MaxSAR which focused on a high throughput approach to expanding chemical diversity. She also was global head of Assay Development and Screening at Sanofi, particularly Phenotypic and Image Based Screening with therapeutic responsibilities in Fibrosis and Oncology. Dr. Garyantes invented the virtual well plate while at Merck, a derivative of which is now being marketing by Curiox, and developed the first clinical instrument for fine structure analysis of DNA at Ciba-Corning Diagnostics which was used at the Mayo Clinic.
Robert M. Goldberg Vice President and co-founder, Center for Medicine in the Public Interest Session C: Personalized Medicine
Robert M. Goldberg is Vice President and co-founder of the Center for Medicine in the Public Interest (www.cmpi.org), a non-profit organization that advocates for consumer access to medical innovation, better health information and personalized healthcare. He is also the founder of CMPI’s Value of Medical Innovation initiative (valueofinnovation.org) that promotes awareness of the value of medical progress and co-founder of Mylifeisworthit.org, an online advocacy project that promotes faster approvals and access to new medicines particularly for cancer.
Prior to founding CMPI, Goldberg was Director of the Manhattan Institute's Center for Medical Progress and Chairman of its 21st Century FDA Task Force that examined the impact of the FDA's Critical Path Initiative on drug development and personalized medicine.
Dr. Goldberg also advises biotech companies on public policy and advocacy concerns. He is on the board and founder of Transforming Medicine: The Elizabeth Kauffman Institute, established to use personalized medicine to match patients to the best combination of treatments for life threatening illnesses. He is also on the board of the Sarcoma Foundation of America.
His academic research focuses on the value of personalized medicine and medical innovation to longevity, economic growth and well-being He is the author of “Tabloid Medicine: How the Internet is Being Used To Hijack Medical Science for Fear and Profit.” (Kaplan, 2011) and writes op-eds and articles for a wide variety of media outlets including Scientific American.
Dr. Goldberg received his PhD in Politics from Brandeis University.
Brian A. Gragnolati Chief Executive Officer and President, Atlantic Health System, Inc. Plenary Speaker
Mr. Brian A. Gragnolati serves as the Chief Executive Officer and President of Atlantic Health System, Inc. With $2.2 billion in revenue and 14,075 employees, the system is comprised of Morristown Medical Center in Morristown, NJ, Overlook Medical Center in Summit, NJ, Newton Medical Center in Newton, NJ, Chilton Medical Center in Pompton Plains, NJ and Goryeb Children’s Hospital in Morristown, NJ. The system also includes Atlantic Rehabilitation, Atlantic Home Care and Hospice, Atlantic Ambulance Corporation and Atlantic Medical Group, a network of more than 600 community-based health care physicians. Atlantic Health System is part of the Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is also a member of AllSpire Health Partners.
Prior to joining Atlantic Health Systems in 2015, he served as Senior Vice President of the Johns Hopkins Health System since March 2011. He was previously President and CEO of Suburban Hospital, a member of Johns Hopkins Medicine. He joined the Suburban Hospital Healthcare System in November 2001.
Mr. Gragnolati has held a number of key executive positions at Baystate Medical Center in Springfield, Massachusetts, and the Medical Center Hospital of Vermont (now Fletcher Allen Healthcare in Burlington, Vermont), the teaching hospital associated with the University of Vermont. Before joining Suburban, he was President and CEO of York Hospital, a 580-bed teaching hospital, and Senior Vice President of WellSpan Health, an integrated healthcare system based in York, Pennsylvania. During his tenure, York Hospital earned the distinction of "100 Top Hospitals" for five consecutive years.
Mr. Gragnolati is a Fellow of the American College of Healthcare Executives and has served on numerous community boards. He is a past Chairman of the Metro Governing Council of the American Hospital Association (AHA) and served as a delegate on the Regional 3 Policy Board. He is the past chair of the Community Hospitals Connection of the Maryland Hospital Association (MHA) and served on the MHA Council of Financial Policy Executive Committee and was previously on the Board of the Montgomery County Chamber of Commerce. He is currently the chairman of the Montgomery Business Development Corporation.
He earned a B.S. degree in Health Systems Analysis from the University of Connecticut and an MBA degree from Western New England College in Massachusetts. He received an Executive Leadership Certificate from the JFK School at Harvard University.
Thomas Hogan Global Tax Leader for the Life Science and Healthcare Industries, Deloitte Session B: Innovative Applications of Tech in Healthcare
Thomas Hogan is Deloitte’s Global Tax Leader for the Life Science and Healthcare Industries. He has more than 30 years of experience specializing in the life sciences industry. He has worked with branded and generic drug manufacturers, biotechnology companies, and medical device companies on various tax consulting and compliance projects. He specializes in tax consulting, planning, and compliance for corporations in service and capital-intensive industries. Mr. Hogan has assisted clients in audits performed by the Internal Revenue service, state tax authorities, and Inland Revenue at the field and appeals levels, and has worked extensively with various government bodies to analyze, establish, or enhance R&D tax incentives and also to analyze their effectiveness. He has also lobbied the Congress and the Treasury on behalf of clients in connection with research credit tax legislation and regulations. Mr. Hogan is the former partner in charge of the Deloitte Global Tax Incentives Team, formerly served as the leader of the National Research Tax Incentives team, and was a member of the International Tax team of another Big Four organization.
Mr. Hogan holds a Bachelor of Science in Business Administration/ Concentration in Accounting, from Montclair State University
Diane Iler-Smith Executive Vice President and Chief Creative Officer, Ogilvy Healthworld Session E: Careers Within Pharma
Diane Iler-Smith is Executive Vice President and Chief Creative Officer at Ogilvy Healthworld, the health behavior experts of Ogilvy & Mather. In this role, Ms. Iler-Smith ensures all agency work meets the highest caliber of creative accomplishment in addition to providing leadership and guidance within the creative department. Prior to rejoining the Ogilvy CommonHealth Worldwide network in 2013, Ms. Iler-Smith served as senior vice president, senior creative director at Biolumina, a pharmaceutical advertising agency in New York City, where she was one of three principals of the startup agency.
With more than 18 years of strategic and creative leadership experience in the pharmaceutical industry, Ms. Iler-Smith began her career as an assistant scientist, genetic toxicology at Schering-Plough, a pharmaceutical company in Kenilworth, NJ, that now takes the name of Merck & Co., Inc., after a merger of the two companies. Among the many senior-level positions she has held through her healthcare career: vice president, associate creative director at Thomas Ferguson Associates, part of CommonHealth; vice president, associate creative director/copy at Integrated Communications; senior vice president, creative director, Ferguson, part of CommonHealth; executive vice president, chief creative officer at Altum, a CommonHealth freestanding, full-service professional advertising and promotion company.
Ms. Iler-Smith holds a BS degree in Biology and Chemistry from Montclair State University and a MS in Biology, Pharmaceutical Medicine from Fairleigh Dickinson University.
Steve LoSardo Senior Principal, Real World Evidence Solutions, IMS Health Session D: Healthcare Analytics
Steve LoSardo is Senior Principal, Real World Evidence Solutions, IMS Health and has more than 24 years of experience providing consulting and information technology services to Pharma, Biotech, Government and other healthcare organizations in the Life Sciences industry. At IMS Health, he specializes on the design and implementation of data management, business intelligence, healthcare informatics, Big Data and Real World Evidence solutions to address the needs of sales, marketing, marketing research, managed markets, clinical and health outcomes research professionals.
Prior to IMS, Mr. LoSardo was with PwC’s Health Industries Advisory group, consulting with Pharma/Life Sciences Companies, Payers and Providers on the evolving role of information technology in healthcare. Previous employment included leadership roles at SDI Health LLC and Verispan LLC, as Vice President of Data Analytics and Services and Vice President of R&D, respectively. He also worked for the Dun & Bradstreet Corporation and began his career at Boehringer Ingelheim Pharmaceuticals.
Mr. LoSardo holds an MBA, specializing in computer information systems, as well as a BBA in management from Hofstra University in New York. He is a member of the Greater Philadelphia Senior Executive Group and is the co-chair for their Life Science subgroup.
Thomas R. Martin PhD, MBA, Director with HIMSS Session D: Healthcare Analytics
Thomas R. Martin, PhD, MBA, is Director with HIMSS, a global, cause-based, not-for-profit organization focused on better health through information technology (IT). In his role he serves as a subject matter expert for telehealth, remote patient monitoring, and digital health. With more than 10 years of experience in healthcare, Dr. Martin previously worked in the telecommunications and healthcare IT industries. He has lived and worked overseas in Australia, traveling extensively in Asia Pacific for business. Dr. Martin began his journey in healthcare working at the Cleveland Clinic Foundation. He has served as project lead for numerous IT implementations and mobile app developments.
He earned his PhD at the University of Delaware. He also holds a Master’s degree in Business Administration from that same institution. Dr. Martin’s research interests include the application of cost benefit analysis, comparative effectiveness, and other economic valuations within the healthcare setting. He holds academic appointments at Georgetown University and St. Joseph’s University.
Erika Milachouski Bayer Healthcare Session E: Careers Within Pharma
Erika Milachouski, Bayer Healthcare, North American Headquarters, Whippany, NJ, is a senior strategist, innovative problem-solver with 5+ years of cross-functional marketing experience within the Bayer sales organization. She has demonstrated ability to influence transformational changes, via strategic thinking and analytics, to provide solutions that breed success. Most notable accomplishments include designated category and shopper loyalty card expert, influencing the realities of form trends within the nutritionals category and recommending a need for a sales digital team to capitalize on emerging shopper marketing opportunities.
John Morrissey Founder, Open Access Foundation; Chair, Scientific Advisory Board for the Richard Schultze Family Foundation Session A: Accelerating New Cures
John Morrissey, Founder, Open Access Foundation and Chair, Scientific Advisory Board for the Richard Schultze Family Foundation. Mr. Morrissey worked for the US Atomic Energy Commission and the joint AEC- NASA Nuclear Propulsion Office for eight years as an engineer/scientist. After receiving an MBA from Stanford, Morrissey served in the Executive Offices of President Nixon and Ford, first as nuclear expert in the team planning the follow-on to the Moon landing, then as economist/finance expert helping on a number of Budget Bureau/ Space and Aero issues, and was later assigned to lead the successful efforts to phase out the Interstate Commerce Commission. Following his government career, he became senior vice president for After17, the world’s largest grocery wholesaler. Through the Open Access Foundation, he has begun an effort to revolutionize the way cancer data is reported to make this data transparent for victims and their families.
Dean J. Paranicas President and Chief Executive Officer, HINJ Opening Remarks
Dean J. Paranicas became the third president and chief executive officer of the HealthCare Institute of New Jersey (HINJ) in March 2011. Prior to joining HINJ, Mr. Paranicas was Vice President, Corporate Secretary and Public Policy for BD. Starting at BD in 1981, he previously served in various legal roles, and also as Director, Corporate Development and Strategic Investments, as Director, Investor Relations, and as Vice President, Investor Relations and Public Affairs.
Mr. Paranicas began his career as an associate attorney with McCarter & English, LLP in Newark, New Jersey. He earned a B.A. Degree With Honors from Rutgers College, Rutgers University, where he was a member of Phi Beta Kappa. He earned a J.D. degree from Rutgers-Newark School of Law, where he was an Editor of the Rutgers Law Review.
Previously, Mr. Paranicas served as HINJ’s Board Secretary and Chair of its Steering Committee.
Mr. Paranicas is a Co-Chair of We Work for Health–New Jersey, is a member of the Board of Directors of the New Jersey Innovation Institute, and serves on the Advisory Board of the Biotechnology High School in Freehold, New Jersey.
Mr. Paranicas is a former member of the Board of Directors of NEHI–The Network for Excellence in Health Innovation and a former Chair of the Board of Trustees of the Foundation for New Jersey Public Broadcasting. He also is a former member of the Rutgers University Board of Governors and the Rutgers University Foundation Board of Overseers, and is a former Chair of the Rutgers University Board of Trustees, where he is now a Trustee Emeritus.
Charko C. Patterson Watson Health Innovations Architect, Watson Life Sciences, IBM Session B: Innovative Applications of Tech in Healthcare
Charko Patterson is a Watson Health Innovations Architect at IBM with responsibility for designing new Real World Evidence (RWE) solutions for the Healthcare and Life Sciences (HCLS) industry. In this role, Mr. Patterson partners with product and IBM Research teams within IBM; leveraging the company’s emerging technology in Analytics, Data Science, Cognitive Computing, as well as open source technologies. He also provides counsel to executive leadership on technical strategy.
Prior to joining the Watson Health Innovations team, Mr. Patterson was an IBM Client Architect and Technical Advisor where he served Life Sciences clients on behalf of IBM by defining solutions and architectures to address business needs.
Mr. Patterson joined IBM in 2009 as an IT Systems Internal Auditor. In this role, he led audits that assessed the controls of internal IBM systems that impacted financial and regulatory reporting.
Mr. Patterson holds a BBA in Management from Pace University’s Lubin School of Business.
Chris Ruli BS '10, senior research analyst for the Advisory Board Company's Healthcare IT group Session E: Careers Within Pharma
Chris Ruli is a senior research analyst for the Advisory Board Company's Healthcare IT group, which focuses on engaging Chief Information Officers across the country. His research topics include mobile technology strategy, IT security, consumer engagement, big data/analytics, and telemedicine. Before joining the IT group, Mr. Ruli was a senior consultant for Crimson, one of the Advisory Board's largest performance technologies, focusing on quality improvement and clinical initiatives around infectious disease, cardiology, and orthopedics.
Mr. Ruli holds a bachelor of science in business administration from Montclair State University, complemented with a master of international affairs with a focus on advanced quantitative analysis and statistics from Columbia University's School of International and Public Affairs.
Mr. Ruli is a Returned Peace Corps Volunteer, serving in Senegal, West Africa. He has worked with several organizations-including the Bill and Melinda Gates Foundation, PATH, Booz Allen Hamilton, and the Clinton Health Access Initiative-on creating and integrating health technologies in sub-Saharan Africa. His previous work has focused on mapping the transmission of infectious diseases, creating economic and statistical models, and building health capacity and integrated technology infrastructure for projects in Zimbabwe, Zambia, Tanzania, Nigeria, and Senegal. He is also a member of MSU's Young Professionals Board.
Philip Scharago PES Consulting, LLC. Session E: Careers Within Pharma
Philip Scharago of PES Consulting, LLC. With over 25 years of diverse professional experience and MBA in Pharm Management and Health/Drug Law MSJ. Extensive and broad-based knowledge in quality assurance, compliance, gov’t/regulatory agency requirements, strategic planning and remediation experience in both medical device, pharmaceutical and clinical settings in a consent decree environment. Specific expertise in medical device (CFR 820), ISO 13485 and 21CFR 210/211.Mr. Scharago is well-recognized in the pharmaceutical/medical device industry and is currently serving as an independent consultant.
Rachel Braun Scherl Co-Owner & Principal SPARK Solutions for Growth Session B: Innovative Applications of Tech in Healthcare
Rachel Braun Scherl is a growth strategy consultant, marketing expert and sought-after public speaker who has become a trusted authority on leadership and entrepreneurship. In her 20+ years as a consultant and entrepreneur, Ms. Braun Scherl has achieved countless gains for her clients as well as her own business, from engineering product re-positioning to regain market dominance, to providing the strategy that has secured strong customer bases for numerous startups. As co-owner and principal of SPARK Solutions for Growth, a consulting firm advising businesses on strategic growth and partnerships, product development and marketing, Ms. Braun Scherl has built an international client base that includes multiple divisions of Johnson & Johnson, Allergan, Pfizer, Merck, Bayer and Deloitte. Her firm’s client retention rate is more than 90 percent, and clients typically retain SPARK as they move to other companies and roles.
Ms. Braun Scherl launched SPARK with business partner Mary Wallace Jaensch as a division of their consulting firm The Jannick Group in 1998, and drove its growth for 10 years before launching her next venture. In 2008 she partnered with healthcare investment firm Quaker BioVentures to create Semprae Laboratories. As President, Ms. Braun Scherl and her team built a company that developed and marketed sexual health and wellness products for women - literally creating a new category in the process. Semprae attracted significant media attention and industry interest, and was sold to Innovus Pharmaceuticals in 2013. Ms. Braun Scherl then returned her attention to SPARK, re-launching the company with her longtime business partner.
Prior to launching The Jannick Group and SPARK, Ms. Braun Scherl was a principal at the Demeter Group, where she contributed to doubling revenues in the first year of her tenure. Previously, Ms. Braun Scherl was a principal at Marketing Corporation of America, where she served as lead consultant and project manager for Johnson & Johnson's global OTC, pharmaceutical and consumer products, and managed strategic engagements for world-class brands including American Express and Disney. Ms. Braun Scherl began her career with Johnson & Johnson, joining a team responsible for managing the company’s flagship TYLENOLTM brand as part of its McNeil consumer division.
As an accomplished speaker, Ms. Braun Scherl is often featured at leadership and entrepreneurship events at colleges, universities and conferences, including Stanford University Graduate School of Business, Duke University, The Fuqua School at Duke University, Yale School of Management, Barnard College, the S.H.E. Summit and Entrepreneurship Week. The noted entrepreneur and motivator has appeared on ABC’s Nightline, CBS News and MSNBC, and been interviewed for major platforms such as The New York Times, San Francisco Chronicle, Forbes, AOL, The Huffington Post and CNN. Ms. Braun Scherl writes a monthly blog for The Huffington Post, and has also written for INC. and contributed a chapter to Linda Ellis Eastman's book The Power of Transformation: Reinventing Your Life, an anthology of insights from business leaders.
Ms. Braun Scherl earned an MBA from Stanford University Graduate School of Business in 1992 after graduating Magna Cum Laude and Phi Beta Kappa from Duke University with a B.A. in Psychology and Human Development. She currently serves on the Duke New York Women’s Executive Board as well as the Center for Entrepreneurship and Innovation for Fuqua School of Business at Duke University. Ms. Braun Scherl serves on the board of Formula XO, Inc., a manufacturer and marketer of beauty products. She is an alumnus of the Wexner Heritage Program, a learning and leadership development program for volunteer leaders in North America.
In 2015, Ms. Braun Scherl was recognized as one of Best Fifty Women in Business by NJBiz. In addition, she is the recipient of SmartCEO’s BRAVA Awards honoring top female CEOS.
John Siekierka Sokol Professor of Medicinal Chemistry and Director of the Sokol Institute of Pharmaceutical Life Sciences Session C: Personalized Medicine
John Siekierka is Sokol Professor of Medicinal Chemistry and Director of the Sokol Institute of Pharmaceutical Life Sciences. Prior to joining Montclair State University in 2007, Dr. Siekierka was director of research and development at the Center for Biomaterials and Advanced Technologies (CBAT) at Johnson & Johnson where he directed research in drug device combination technologies. Dr. Siekierka also held positions as senior research fellow and Head of Immunosuppression Research at Johnson & Johnson Pharmaceutical Research and Development, L.L.C. as well as senior research positions at Merck Research Laboratories andthe Roche Institute of Molecular Biology. Dr. Siekierka is a graduate of Seton Hall University (B.S.), City University of New York (M.S.) and New York University (PhD).
Jay A. Tischfield Duncan and Nancy MacMillan Distinguished Professor of Genetics, Pediatrics and Psychiatry, Executive Director of the Human Genetics Institute of New Jersey and Founder, CEO and Scientific Director of RUCDR Infinite Biologics® Session C: Personalized Medicine
Jay A. Tischfield, is the Duncan and Nancy MacMillan Distinguished Professor of Genetics, Pediatrics and Psychiatry, Executive Director of the Human Genetics Institute of New Jersey, and Founder, CEO and Scientific Director of RUCDR Infinite Biologics®. His over 250 publications describe the genetics of complex diseases including addictions and mental disorders, the origins of genetic variation, the genetics of phospholipases and other topics. Dr. Tischfield is board accredited in two Medical Genetics specialties, a Founding Fellow of the American College of Medical Genetics and a Fellow of the American Association for the Advancement of Science. He served as a biomedical infrastructure advisor to Singapore for nearly two decades. He directs the collection, banking and sample analyses for pharmaceutical industry, federal and foundation-funded projects involving hundreds of thousands of human subjects. Dr. Tischfield is among the top five percent of National Institutes of Health-funded researchers for over 39 years, with over $375 million in total funding during the past 16 years at Rutgers.
Don Wetherhold CEO, Aprecia Session A: Accelerating New Cures
Don Wetherhold was named CEO of Aprecia in 2013, prior to which he served as Senior Vice President, long-term care at Omnicare, Inc. Mr. Wetherhold was Aprecia's Corporate Commercialization Officer previous to his time at Omnicare.
Mr. Wetherhold has over 27 years of experience in the healthcare industry, including key leadership roles and management positions at Omnicare, Cardinal Health, Snyder Healthcare Sales, and Solvay Pharmaceuticals. He has also served as Prasco Laboratories' Senior Vice President and General Manager of Hampton Laine, Prasco's branded pharmaceutical business.
Diane Wuest President, GNS Healthcare Session C: Personalized Medicine
Diane Wuest is President, GNS Healthcare, and develops strategic relationships with precision medicine partners to develop and commercialize computer models capable of elucidating disease mechanisms and advancing drug discovery and development. Dr. Wuest manages ongoing alliances and leverages internal marketing, sales, and product development teams to implement various business development initiatives. Prior to GNS Healthcare, she worked at Genentech, where she led a Phase III interdisciplinary clinical team for an oncology therapeutic, and established department-wide business processes to improve efficiency. Dr. Wuest obtained a PhD in chemical and biomolecular engineering from the University of Delaware where she focused in neuroscience therapeutics and supplemented her technical studies with MBA coursework and establishing STEM outreach initiatives at the Delaware Biotechnology Institute. She also holds a B.S. in chemical engineering from Cornell University.